Trial Profile
A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2020
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.